MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss applicable
to common...
-$8,220,785
(15.84%↑ Y/Y)
Net loss
attributable to...
-$1,173,104
(-128.68%↓ Y/Y)
Net loss
-$9,393,889
(8.63%↑ Y/Y)
Gross Product Revenue
$4,878,720
Loss before income
taxes
-$9,129,649
(8.86%↑ Y/Y)
Income tax expense
$264,240
(0.00%↑ Y/Y)
Revenue
$3,944,111
Grosstonet Adjustments
$934,609
Operating loss
-$9,019,208
(10.16%↑ Y/Y)
Total other income
(expense)
-$110,441
(-588.50%↓ Y/Y)
Gross profit
$3,154,903
Interest income
$45,097
(99.47%↑ Y/Y)
Cost of revenues
$789,208
Total operating
expenses
$12,174,111
(21.26%↑ Y/Y)
Interest expense
$155,538
General and
administrative
$5,720,727
(6.18%↑ Y/Y)
Stock-based compensation
general and...
$4,280,227
(69.53%↑ Y/Y)
Research and development
$1,599,719
(-24.79%↓ Y/Y)
Amortization of in-process
research and development
$573,438
Back
Back
Income Statement
source: myfinsight.com
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)